Novel proteins from Actinobacillus pleuropneumoniae

a technology of actinobacteria and proteins, applied in the field of animal health, can solve the problems of limited cross-protective response induced by natural infection, inability to identify possible differences between the specificity of antibodies during primary versus secondary responses, and inability to isolate individual components or combinations of individual components from apps

Inactive Publication Date: 2004-10-07
ANKENBAUER ROBERT G +6
View PDF12 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the patterns of cross-reactivity / cross-protection induced by such components do not cover all twelve APP serotypes.
In addition, immunization with isolated individual components or combinations of individual components from APP have so far failed to confer protection from challenge with some heterologous serotypes (unpublished observations).
Thus, it can be postulated that the cross-protective responses induced by natural infection are limited to specific serotype clusters.
Such an approach does not allow the identification of possible differences between the antibody specificities represented during primary versus secondary responses, nor the identification of dominant specificities at the infection site that are likely to be responsible for protection upon secondary encounter with the pathogen.
Naive cells migrate relatively homogeneously to secondary lymphoid tissues, but they home poorly to non-lymphoid tissues.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel proteins from Actinobacillus pleuropneumoniae
  • Novel proteins from Actinobacillus pleuropneumoniae
  • Novel proteins from Actinobacillus pleuropneumoniae

Examples

Experimental program
Comparison scheme
Effect test

example 10

Animal Study to Test Efficacy of Various Antigen Combinations

10.1 Materials and Methods

[0218] Fifty apparently healthy, crossbred pigs (approximately 6.5 weeks of age) were obtained from a herd with no history of APP disease or vaccination. Animals were randomly assigned by litter and by ApxII cytolytic neutralization antibody titer to five groups of 10 pigs (98% of the animals had serum neutralization titers <1:200 prior to the initiation of study). Pigs were acclimated for one week prior to initiation of study.

[0219] Animals were vaccinated with 2 ml of the appropriate vaccine (APP proteins with pp and without signal sequence) or placebo by the intramuscular route (IM; left neck muscle) on day 0, when pigs were approximately 7.5 weeks of age. After 3 weeks, animals were boosted with a second 2 ml dose (IM; right neck muscle). TABLE 6 identifies the vaccines used for first and second vaccinations of the 5 groups of pigs.

6TABLE 6 Vaccine Group Vaccine Components A 75 .mu.g pp-OmpW 7...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightsaaaaaaaaaa
molecular weightsaaaaaaaaaa
molecular weightsaaaaaaaaaa
Login to view more

Abstract

The present invention is directed to five novel, low molecular weight proteins from Actinobacillus pleuropneumoniae (APP), which are capable of inducing, or contributing to the induction of, a protective immune response in swine against APP. The present invention is further directed to polynucleotide molecules having nucleotide sequences that encode the proteins, as well as vaccines comprising the proteins or polynucleotide molecules, and methods of making and using the same.

Description

[0001] This application claims priority from provisional application Serial No. 60 / 105,285, which was filed on Oct. 22, 1998, and which is incorporated by reference in its entirety herein.1. FIELD OF THE INVENTION[0002] The present invention is in the field of animal health, and is directed to vaccines that protect swine against Actinobacillus pleuropneumoniae. More particularly, the present invention is directed to novel antigenic proteins shared by multiple serotypes of A. pleuropneumoniae, DNA molecules encoding the proteins, vaccines against APP comprising the proteins, and diagnostic reagents.2. BACKGROUND OF THE INVENTION[0003] A. pleuropneumoniae (hereinafter referred to as "APP") is a Gram negative coccobacillus recognized as one of the most important swine pneumonic pathogens (Shope, R. E., 1964, J. Exp. Med. 119:357-368; Sebunya, T. N. K. and Saunders, J. R., 1983, J. Am. Vet. Med. Assoc. 182:1331-1337). Twelve different serotypes have been recognized which vary in geograp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00A61K39/102C07K14/285G01N33/569
CPCA61K39/00A61K39/102A61K2039/52C07K14/285G01N33/56911
Inventor ANKENBAUER, ROBERT G.BAARSCH, MARY JOCAMPOS, MANUELKEICH, ROBINROSEY, EVERETTSUITER, BRIANWARREN-STEWART, LYNN
Owner ANKENBAUER ROBERT G
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap